Hyperglobulinemia as a marker in the development of immune deficiency and complications in inflammatory breast cancer patients with type 2 diabetes mellitus
Dynamic monitoring of cryoglobulinemia throughout the postoperative period in patients with inflammatory breast cancer may indicate changes in their concentration in blood serum depending on the time of observation. The study aimed to determine cryoglobulin levels and plasma glucose levels as influencing factors in the development of immune system deficiency in inflammatory breast cancer, which could lead to different types of postoperative complications. In all patients, blood serum cryoglobulinemia conditions and plasma glucose levels were observed on the third, fifth and seventh day after the procedure and the content of lymphocyte subpopulations in the early postoperative period. Twenty patients with inflammatory breast cancer were divided into two groups: the first included 10 patients with normal levels of cryoglobulins in blood serum 60–80 mg/l (less than 108 mg)/l, corresponding to level 0-I of cryoglobulinemia and blood glucose range 4.4–6.6 mmol/l. The second group included 10 patients with primary hypercryoglobulinemia 298.6±2.5 mg/l; 1.3±0.08% (more than 280 mg/l), corresponding to level II-III of cryoglobulinemia and blood glucose range over 10.0 mmol/l. In both groups of patients, there was an increase in the concentration of cryoglobulins and plasma glucose levels on the third day after surgery. Thus, studies have shown that patients with cryoglobulinemia and type 2 diabetes mellitus operated for tumor-induced inflammatory breast cancer have formed a secondary immune deficiency. This is determined by abnormalities in the cellular and humoral immune system and as a consequence of developing postoperative inflammatory complications in patients with diabetes mellitus.